The FDA granted a new indication for upadacitinib (Rinvoq, AbbVie) for the treatment of adults with moderate to severe active Crohn’s disease who have not responded adequately to or cannot tolerate one or more tumor necrosis factor blockers.
The indication joins a previous approval for use in certain patients with ulcerative colitis, as well as other non-gastrointestinal diseases. The current indication for patients with Crohn's disease is supported by data from two induction studies,